NASDAQ:ATNX Athenex (ATNX) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range$0.20▼$1.7652-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability About Athenex (NASDAQ:ATNX) StockAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Read More Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNX Stock News HeadlinesMay 17, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 16, 2023 | uk.finance.yahoo.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 16, 2023 | msn.comBuffalo Billion project Athenex files for Chapter 11 bankruptcyMay 16, 2023 | americanbankingnews.comAthenex, Inc. (NASDAQ:ATNX) Short Interest Down 9.9% in AprilMay 15, 2023 | msn.comAthenex files Chapter 11May 15, 2023 | bizjournals.comAthenex files for bankruptcy, announces plans to sell assetsMay 15, 2023 | msn.comWhy Athenex (ATNX) Stock Is Getting Obliterated MondayMay 31, 2023 | Edge On The Street (Ad)146 Pounds of Graphite Needed for Each EVGraphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.May 15, 2023 | finance.yahoo.comAthenex Voluntarily Filed For Chapter 11 Proceedings, Shares PlungeMay 15, 2023 | marketwatch.comAthenex Shares Tumble Premarket After Chapter 11 Filing >ATNXMay 15, 2023 | msn.comWhy Is Athenex (ATNX) Stock Down 54% Today?May 15, 2023 | markets.businessinsider.comAthenex Files For Chapter 11 BankruptcyMay 14, 2023 | news.yahoo.comDrugmaker Athenex voluntarily files for U.S. Chapter 11 proceedingsMay 14, 2023 | finance.yahoo.comAthenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessMay 10, 2023 | bizjournals.comPine Pharmaceuticals assumes part of Athenex’s business and 50 workersMay 1, 2023 | finance.yahoo.comQuantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCOApril 24, 2023 | finance.yahoo.comAthenex, Inc. (ATNX) Stock Historical Prices & Data - Yahoo FinanceApril 18, 2023 | bizjournals.comCalifornia-based Biomed Industries offers to buy AthenexApril 1, 2023 | americanbankingnews.comShort Interest in Athenex, Inc. (NASDAQ:ATNX) Increases By 20.6%March 25, 2023 | americanbankingnews.comAthenex, Inc. to Post FY2023 Earnings of ($1.45) Per Share, SVB Leerink Forecasts (NASDAQ:ATNX)March 24, 2023 | americanbankingnews.comSVB Leerink Comments on Athenex, Inc.'s Q1 2023 Earnings (NASDAQ:ATNX)March 23, 2023 | finance.yahoo.comAthenex (ATNX) Upgraded to Buy: Here's WhyMarch 21, 2023 | americanbankingnews.comAthenex (NASDAQ:ATNX) Rating Lowered to Neutral at LADENBURG THALM/SH SHFebruary 14, 2023 | finance.yahoo.comAthenex Announces a Reverse Stock SplitJanuary 3, 2023 | finance.yahoo.comAthenex Announces MHRA Decision on Oral PaclitaxelDecember 31, 2022 | msn.comAthenex to close Clarence plant, lay off 92 employeesSee More Headlines Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNX Company Calendar Last Earnings11/04/2021Today5/31/2023Next Earnings (Estimated)7/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNX CUSIPN/A CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-103,430,000.00 Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 Key ExecutivesYiu Nam LauChairman & Chief Executive OfficerJeff YordonCOO & President-Athenex Pharmaceutical DivisionJoe AnnoniChief Financial OfficerDarrel P. CohenChief Medical OfficerWilliam ZuoPresident-China OperationsKey CompetitorsNovaBay PharmaceuticalsNYSE:NBYCalithera BiosciencesNASDAQ:CALAAyala PharmaceuticalsNASDAQ:ADXSSciSparcNASDAQ:SPRCStatera BiopharmaNASDAQ:STABView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 403,967 shares on 5/17/2023Ownership: 0.261%Perceptive Advisors LLCSold 14,755,844 shares on 5/16/2023Ownership: 8.965%Alyeska Investment Group L.P.Sold 1,900,000 shares on 5/16/2023Ownership: 1.154%Geode Capital Management LLCSold 532,842 shares on 5/16/2023Ownership: 0.318%Schonfeld Strategic Advisors LLCSold 558,858 shares on 5/15/2023Ownership: 0.279%View All Insider TransactionsView All Institutional Transactions ATNX Stock - Frequently Asked Questions Should I buy or sell Athenex stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares. View ATNX analyst ratings or view top-rated stocks. When is Athenex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our ATNX earnings forecast. How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. The firm had revenue of $32.30 million for the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative net margin of 86.31% and a negative trailing twelve-month return on equity of 727.79%. During the same quarter in the prior year, the firm earned ($0.44) EPS. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). When did Athenex IPO? (ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager. What is Athenex's stock symbol? Athenex trades on the NASDAQ under the ticker symbol "ATNX." Who are Athenex's major shareholders? Athenex's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.96%), Alyeska Investment Group L.P. (1.15%), BlackRock Inc. (0.77%), UBS Group AG (0.77%), Acadian Asset Management LLC (0.73%) and Renaissance Technologies LLC (0.68%). Insiders that own company stock include Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan and William Wei Zuo. View institutional ownership trends. How do I buy shares of Athenex? Shares of ATNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Athenex make? Athenex (NASDAQ:ATNX) has a market capitalization of $0.00 and generates $102.82 million in revenue each year. The company earns $-103,430,000.00 in net income (profit) each year or ($15.88) on an earnings per share basis. How many employees does Athenex have? The company employs 652 workers across the globe. How can I contact Athenex? Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The official website for the company is www.athenex.com. The company can be reached via phone at (716) 427-2950 or via email at stevenrubis@athenex.com. This page (NASDAQ:ATNX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.